Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 (Cadonilimab) + Lenvatinib in Advanced HCC
NCT04444167Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2020
- Primary completion
- Nov 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jul 2020; status: completed.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04444167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444167.